SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
| FROM | TO | |
|---|---|---|
| OPTHEA LIMITED | 14/12/2015 | |
| CIRCADIAN TECHNOLOGIES LIMITED | 14/12/2015 |
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)Securities of the company have been suspended for over three months, as detailed in the table unfiled periodic reports, deadlines for the oldest report, and two-year plans for resuming trade. Failure to meet these deadlines leads to removal from the official list after the specified trading day. | 15/10/2025 |
The company will hold its annual general meeting virtually on November 11, 2025, 9:00am (Melbourne time). | 10/10/2025 |
The company has received an A$10.8 million R&D tax incentive for costs incurred in 2024/2025, aiding development of sozinibercept. | 06/10/2025 |
The company will hold its annual general meeting at 9am (AEDT) on 11 November 2025. | 16/09/2025 |
The company lodges its annual report to shareholders and corporate governance statement. | 15/09/2025 |
Shareholders in this company should consider crystallising a capital loss in 2025/26 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person. | 12/09/2025 |
S&P Dow Jones Indices announced a quarterly rebalance of the S&P/ASX Indices for September 2025, effective before trading opens on September 22, 2025. | 05/09/2025 |
The company releases its application for quotation of securities. | 05/09/2025 |
The company releases its preliminary final report. | 29/08/2025 |
The company releases its Corporate Update Investor Call Presentation. | 20/08/2025 |
The company lodges its application for quotation of securities. | 19/08/2025 |
The company has reached a successful settlement of the Development Funding Agreement with two investors, Ocelot SPV LP and Sanba II Investment Company. The DFA was terminated in March 2025 due to unmet clinical trials, triggering payments of up to USD680 million. The company has now reached a binding agreement with the DFA Investors to terminate the DFA, resulting in an equity subscription deed. | 19/08/2025 |
The company lodges its application for quotation of securities. | 08/08/2025 |
The company releases its quarterly activities/appendix 4C cash flow report. | 30/07/2025 |
Entities with securities suspended for over three months must lodge periodic reports, meet a 1 year deadline for the oldest outstanding report, and execute plans for resuming trading to ASX's satisfaction. Failure to meet deadlines results in removal from the official list. | 16/07/2025 |
The company provides a corporate update. Opthea Limited has resigned four directors due to negative Phase 3 trials and a 65% workforce reduction. The company is in active negotiations with its Development Funding Agreement investors to find the best outcome for shareholders. Trading in Opthea's listed securities has been suspended until further clarity is provided. | 02/06/2025 |
The company lodges its quarterly activities and appendix 4C. | 30/04/2025 |
The company has announced a 65% workforce reduction to preserve cash following the termination of its COAST and ShORe Phase 3 clinical trials. The reduction will be effective from May 1, 2025, with one-off costs of approximately $4.5M and monthly employee costs of $1M. Opthea estimates unaudited cash and cash equivalents of $100M at the end of March 2025. | 10/04/2025 |
The company's securities were suspended due to breach of Listing Rule 12.2, and will continue suspension until compliance is confirmed. | 31/03/2025 |
The company discontinues wet AMD trials, including COAST and ShORe, due to accelerated topline results and failure to meet primary endpoint. Opthea and DFA Investors agree to terminate both trials. | 31/03/2025 |
The company has announced the results of its COAST Phase 3 clinical trial. The trial did not meet the primary endpoint of mean change in best corrected visual acuity from baseline to week 52. | 24/03/2025 |
The securities of Opthea Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPT, pending the release of an announcement regarding clinical trial results. | 19/03/2025 |
The following Options of Opthea Limited will be reinstated to quotation from the commencement of trading on Thursday, 18 July 2024: OPTOB | 17/07/2024 |
The options of Opthea Limited will be suspended immediately in accordance with Listing Rule 17.3, as there will be no deferred settlement trading. The options are expected to be quoted on a normal settlement basis on Thursday, 18 July 2024. The suspension only applies to OPT's options (ASX: OPTOB) and does not apply to any other quoted securities of OPT. | 11/07/2024 |
The suspension of trading in the options (ASX: OPTOA) of Opthea Limited will be lifted immediately. | 22/09/2023 |
The options of Opthea Limited will be suspended immediately in accordance with Listing Rule 17.3, as there will be no deferred settlement trading. The options are expected to be quoted on a normal settlement basis on Friday, 22 September 2023. The suspension only applies to OPT's options and does not apply to any other quoted securities of OPT. | 15/09/2023 |
name changed from Circadian Technologies Limited | 14/12/2015 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 04/04/2019 | Megan Baldwin | -667,000 | $0.660 | $440,220.00 |
| 24/04/2017 | Michael Sistenich | 200,178 | $0.930 | $186,166.00 |
| 24/05/2013 | Robert Klupacs | 5,000 | $0.250 | $1,250.00 |
| 22/05/2013 | Robert Klupacs | 42,000 | $0.260 | $10,920.00 |
| 16/05/2013 | Tina McMeckan | 30,000 | $0.251 | $7,539.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Jeremy Levin | Chairman | 12/10/2020 |
| Lawrence Gozlan | Non Exec Director | 24/07/2020 |
| Kathy Connell | Non Exec Director | 15/11/2024 |
| Karen Adams | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
